A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.
Doripenem has been studied across 7 research domains including 🫘 Kidney, 😴 Sleep, 🧠 Focus & Attention, 🔥 Metabolic, 🫁 Respiratory. The primary research focus is 🫘 Kidney with 6% of studies addressing this area.
The following compounds share molecular targets with Doripenem, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Doripenem is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.